Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
- @IpsenGroup #AnnualReport : review of the year 2016 https://t.co/3nLPxyz0Ue
- @IpsenGroup RT @EFPIA: #WeWontRest until there is a future without cancer. Thank you for your pledge @IpsenGroup https://t.co/Mq4MkYsLdu https://t.co/t…
- @IpsenGroup Ipsen's #annualreport is available on line: discover CEO David Meek's vision on Ipsen in 2016 https://t.co/hP2Fr3dBaQ
- @IpsenGroup RT @EFPIA: #WeWontRest until patients and their families have better days. Thank you @IpsenGroup for your pledge! https://t.co/1H9kNwysQi h…
RESEARCH & DEVELOPMENT
Our commitment is based on a strengthened partnership policy, a promising pipeline, two specialized technological platforms and three benchmark R&D centers across the globe.